These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 33465681)

  • 1. Palbociclib and cetuximab in cetuximab-resistant human papillomavirus-related oropharynx squamous-cell carcinoma: A multicenter phase 2 trial.
    Oppelt P; Ley JC; Worden F; Palka K; Maggiore R; Liu J; Adkins D
    Oral Oncol; 2021 Mar; 114():105164. PubMed ID: 33465681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Palbociclib and cetuximab compared with placebo and cetuximab in platinum-resistant, cetuximab-naïve, human papillomavirus-unrelated recurrent or metastatic head and neck squamous cell carcinoma: A double-blind, randomized, phase 2 trial.
    Adkins DR; Lin JC; Sacco A; Ley J; Oppelt P; Vanchenko V; Komashko N; Yen CJ; Wise-Draper T; Lopez-Picazo Gonzalez J; Radulovic S; Shen Q; Thurm H; Martini JF; Hoffman J; Huang X; Melichar B; Tahara M
    Oral Oncol; 2021 Apr; 115():105192. PubMed ID: 33571736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial.
    Adkins D; Ley J; Neupane P; Worden F; Sacco AG; Palka K; Grilley-Olson JE; Maggiore R; Salama NN; Trinkaus K; Van Tine BA; Steuer CE; Saba NF; Oppelt P
    Lancet Oncol; 2019 Sep; 20(9):1295-1305. PubMed ID: 31351869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of palbociclib, a selective cyclin dependent kinase 4/6 inhibitor, in combination with cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma.
    Michel L; Ley J; Wildes TM; Schaffer A; Robinson A; Chun SE; Lee W; Lewis J; Trinkaus K; Adkins D
    Oral Oncol; 2016 Jul; 58():41-8. PubMed ID: 27311401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Potential for Selective Cyclin-Dependent Kinase 4/6 Inhibition in the Therapy for Head and Neck Squamous Cell Carcinoma.
    Adkins D; Ley J; Cohen J; Oppelt P
    Cancer J; 2022 Sep-Oct 01; 28(5):377-380. PubMed ID: 36165726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase I Study of the CDK4/6 Inhibitor Palbociclib in Combination with Cetuximab and Radiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma.
    Ngamphaiboon N; Pattaranutaporn P; Lukerak S; Siripoon T; Jinawath A; Arsa L; Shantavasinkul PC; Taonam N; Trachu N; Jinawath N; Kositwattanarerk A; Sananmuang T; Jiarpinitnun C
    Clin Cancer Res; 2024 Jan; 30(2):294-303. PubMed ID: 37982827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Palbociclib-based high-throughput combination drug screening identifies synergistic therapeutic options in HPV-negative head and neck squamous cell carcinoma.
    Gu Z; Shi C; Li J; Han Y; Sun B; Zhang W; Wu J; Zhou G; Ye W; Li J; Zhang Z; Zhou R
    BMC Med; 2022 May; 20(1):175. PubMed ID: 35546399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I study of avelumab, palbociclib, and cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma.
    Dennis MJ; Sacco AG; Qi Y; Bykowski J; Pittman E; Chen R; Messer K; Cohen EEW; Gold KA
    Oral Oncol; 2022 Dec; 135():106219. PubMed ID: 36279618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group.
    Marur S; Li S; Cmelak AJ; Gillison ML; Zhao WJ; Ferris RL; Westra WH; Gilbert J; Bauman JE; Wagner LI; Trevarthen DR; Balkrishna J; Murphy BA; Agrawal N; Colevas AD; Chung CH; Burtness B
    J Clin Oncol; 2017 Feb; 35(5):490-497. PubMed ID: 28029303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Palbociclib inhibits the progression of head and neck cancer and improves the Cetuximab response under specific condition in vitro and in vivo.
    Li R; Wang Q; Zhao Y; Zhu Y; Wang X
    Mol Biol Rep; 2024 Mar; 51(1):455. PubMed ID: 38536540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy).
    Edelman MJ; Redman MW; Albain KS; McGary EC; Rafique NM; Petro D; Waqar SN; Minichiello K; Miao J; Papadimitrakopoulou VA; Kelly K; Gandara DR; Herbst RS
    J Thorac Oncol; 2019 Oct; 14(10):1853-1859. PubMed ID: 31302234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Palbociclib Renders Human Papilloma Virus-Negative Head and Neck Squamous Cell Carcinoma Vulnerable to the Senolytic Agent Navitoclax.
    Gadsden NJ; Fulcher CD; Li D; Shrivastava N; Thomas C; Segall JE; Prystowsky MB; Schlecht NF; Gavathiotis E; Ow TJ
    Mol Cancer Res; 2021 May; 19(5):862-873. PubMed ID: 33495400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.
    Guigay J; Aupérin A; Fayette J; Saada-Bouzid E; Lafond C; Taberna M; Geoffrois L; Martin L; Capitain O; Cupissol D; Castanie H; Vansteene D; Schafhausen P; Johnson A; Even C; Sire C; Duplomb S; Evrard C; Delord JP; Laguerre B; Zanetta S; Chevassus-Clément C; Fraslin A; Louat F; Sinigaglia L; Keilholz U; Bourhis J; Mesia R; ; ;
    Lancet Oncol; 2021 Apr; 22(4):463-475. PubMed ID: 33684370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase 2 Open Label, Single-Arm Trial to Evaluate the Combination of Cetuximab Plus Taxotere, Cisplatin, and 5-Flurouracil as an Induction Regimen in Patients With Unresectable Squamous Cell Carcinoma of the Head and Neck.
    Mesía R; Vázquez S; Grau JJ; García-Sáenz JA; Lozano A; García C; Carles J; Irigoyen A; Mañós M; García-Paredes B; del Barco E; Taberna M; Escobar Y; Cruz JJ;
    Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):289-96. PubMed ID: 26675064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS study.
    Lonardi S; Prete AA; Morano F; Messina M; Formica V; Corsi DC; Orciuolo C; Frassineti GL; Zampino MG; Casagrande M; Masi G; Ronzoni M; Scartozzi M; Buonadonna A; Mosconi S; Ratti M; Sartore-Bianchi A; Tamburini E; Prisciandaro M; Bergamo F; Spada M; Corallo S; Vettore V; Loupakis F; Fassan M; Del Bianco P; Zagonel V; Pietrantonio F
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34815354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial.
    Ferris RL; Saba NF; Gitlitz BJ; Haddad R; Sukari A; Neupane P; Morris JC; Misiukiewicz K; Bauman JE; Fenton M; Jimeno A; Adkins DR; Schneider CJ; Sacco AG; Shirai K; Bowles DW; Gibson M; Nwizu T; Gottardo R; Manjarrez KL; Dietsch GN; Bryan JK; Hershberg RM; Cohen EEW
    JAMA Oncol; 2018 Nov; 4(11):1583-1588. PubMed ID: 29931076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of combination treatment with S-1/cetuximab in patients with platinum-ineligible recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Taguchi J; Shimizu Y; Ariga S; Goda T; Ohhara Y; Honma R; Noguchi T; Takeuchi S; Kinoshita I; Amano T; Mizumachi T; Kano S; Takahara M; Abe T; Homma A; Dosaka-Akita H
    Int J Clin Oncol; 2021 Jan; 26(1):51-58. PubMed ID: 32996023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term response in patient with recurrent oropharyngeal carcinoma treated with cetuximab, docetaxel and cisplatin (TPEx) as first-line treatment followed by cetuximab maintenance.
    Guigay J; Even C; Mayache-Badis L; Debbah M; Saada-Bouzid E; Tao Y; Deschamps F; Janot F; Lezghed N; Michel C
    Oral Oncol; 2017 May; 68():114-118. PubMed ID: 28347701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer.
    Jimeno A; Shirai K; Choi M; Laskin J; Kochenderfer M; Spira A; Cline-Burkhardt V; Winquist E; Hausman D; Walker L; Cohen RB
    Ann Oncol; 2015 Mar; 26(3):556-61. PubMed ID: 25524478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study.
    Chen AM; Felix C; Wang PC; Hsu S; Basehart V; Garst J; Beron P; Wong D; Rosove MH; Rao S; Melanson H; Kim E; Palmer D; Qi L; Kelly K; Steinberg ML; Kupelian PA; Daly ME
    Lancet Oncol; 2017 Jun; 18(6):803-811. PubMed ID: 28434660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.